Granted Patent
B2
US 12,486,336 · App. 18/054,776 · Granted Dec 2, 2025
Binding molecules with modified J-chain
Inventors:
Bruce A. Keyt (Hillsborough, CA); Leonard G. Presta (San Francisco, CA); Ramesh Baliga (Redwood City, CA)
Assignee:
IGM BIOSCIENCES, INC.
C07K16/468A61K39/39541A61K39/39558C07K16/28C07K16/2809C07K16/2881C07K16/2887A61K2039/505A61P27/00A61P35/02C07K2317/24C07K2317/31C07K2317/35C07K2317/52C07K2317/569C07K2317/622C07K2317/734C07K2317/90C07K2319/31C07K2319/735C07K2319/91
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Claims (13)
1 . An IgM, IgA, IgG/IgM or IgG/IgA antibody or an antigen binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a modified J chain that comprises an absorption, distribution, metabolism and/or excretion (ADME)-modulating moiety, wherein the ADME-modulating moiety comprises a human IgG Fc domain that binds to FcRn, wherein the modified J chain sequence comprises a direct or indirect fusion of the ADME-modulating moiety to the C-terminus or the N-terminus of a human J chain sequence, wherein the modified J chain sequence comprises the native human J chain sequence of SEQ ID NO: 1.
2 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 1 , wherein the ADME-modulating moiety is introduced by indirect fusion through a peptide linker.
3 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 1 , wherein the ADME-modulating moiety is introduced into the native human J chain sequence of SEQ ID NO: 1 at the C-terminus.
4 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 1 , wherein the ADME-modulating moiety is introduced into the native human J chain sequence of SEQ ID NO: 1 at the N-terminus.
5 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 2 , wherein the peptide linker is about 10 to 20 amino acids long.
6 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 5 , wherein the peptide linker is 15 to 20 amino acids long.
7 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 6 , wherein the peptide linker is 15 amino acids long.
8 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 2 , wherein the modified J chain is in an ADME-linker-J orientation, with the ADME-modulating moiety at an N-terminus of the modified J chain.
9 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 2 , wherein the modified J chain is in a J-linker-ADME orientation, with the ADME-modulating moiety at a C-terminus of the modified J chain.
10 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 1 , wherein the modified J chain further comprises a second binding moiety.
11 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 10 , wherein the ADME-modulating moiety is located at an N-terminus of the modified J chain, and the second binding moiety is located at a C-terminus of the modified J chain.
12 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 10 , wherein the ADME-modulating moiety is located at a C-terminus of the modified J chain, and the second binding moiety is located at an N-terminus of the modified J chain.
13 . The IgM, IgA, IgG/IgM or IgG/IgA antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof is an IgM antibody.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 15, 2022
From: IGM BIOSCIENCES A/S
To: IGM BIOSCIENCES, INC.
Reel/Frame 061780/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 14, 2022
From: KEYT, BRUCE ALAN; PRESTA, LEONARD GEORGE; BALIGA, RAMESH
To: IGM BIOSCIENCES A/S
Reel/Frame 061758/0684 →
Continuity (4)
Continuation
15764859
Provisional Application
62235518
· Sep 30, 2015
References Cited (400)
US 4816567A
· Cabilly
· 1989
[cited by applicant]
US 5434340A
· Krimpenfort
· 1995
[cited by applicant]
US 5798229A
· Strittmatter
· 1998
[cited by applicant]
US 5831034A
· Katinger
· 1998
[cited by applicant]
US 5911989A
· Katinger
· 1999
[cited by applicant]
US 6165463A
· Platz
· 2000
[cited by applicant]
US 6284536B1
· Morrison
· 2001
[cited by applicant]
US 6476198B1
· Kang
· 2002
[cited by applicant]
US 6676924B2
· Hansen
· 2004
[cited by applicant]
US 7074403B1
· Goldenberg
· 2006
[cited by applicant]
US 7109304B2
· Hansen
· 2006
[cited by applicant]
US 7138496B2
· Hua
· 2006
[cited by applicant]
US 7151164B2
· Hansen
· 2006
[cited by applicant]
US 7238785B2
· Govindan
· 2007
[cited by applicant]
US 7251164B2
· Okhonin
· 2007
[cited by applicant]
US 7282567B2
· Goldenberg
· 2007
[cited by applicant]
US 7300655B2
· Hansen
· 2007
[cited by applicant]
US 7311912B1
· Hein
· 2007
[cited by applicant]
US 7312318B2
· Hansen
· 2007
[cited by applicant]
US 7387773B2
· Murray
· 2008
[cited by applicant]
US 7402312B2
· Rosen
· 2008
[cited by applicant]
US 7541440B2
· Goldenberg
· 2009
[cited by applicant]
US 7601351B1
· Rosen
· 2009
[cited by applicant]
US 7612180B2
· Goldenberg
· 2009
[cited by applicant]
US 7709615B2
· Irie
· 2010
[cited by applicant]
US 7932360B2
· Van Berkel
· 2011
[cited by applicant]
US 7951378B2
· Larrick
· 2011
[cited by applicant]
US 8066994B2
· Gillies
· 2011
[cited by applicant]
US 8114965B2
· Maddon
· 2012
[cited by applicant]
US 8153125B2
· Watkins
· 2012
[cited by applicant]
US 8257703B2
· Irie
· 2012
[cited by applicant]
US 8333971B2
· Goldenberg
· 2012
[cited by applicant]
US 8337844B2
· Carr
· 2012
[cited by applicant]
US 8377435B2
· Bhat
· 2013
[cited by applicant]
US 8871216B2
· Chang
· 2014
[cited by applicant]
US 9173961B2
· Deckert
· 2015
[cited by applicant]
US 9409976B2
· Teng
· 2016
[cited by applicant]
US 9458241B2
· Bhat
· 2016
[cited by applicant]
US 9938347B2
· Wang
· 2018
[cited by applicant]
US 9951134B2
· Keyt
· 2018
[cited by examiner]
US 20020168367A1
· Larrick
· 2002
[cited by applicant]
US 20040156826A1
· Dangond
· 2004
[cited by applicant]
US 20050003431A1
· Wucherpfennig
· 2005
[cited by applicant]
US 20050129616A1
· Salcedo
· 2005
[cited by applicant]
US 20050287153A1
· Dennis
· 2005
[cited by applicant]
US 20060063234A1
· Jones
· 2006
[cited by applicant]
US 20070014720A1
· Gazit-Bornstein
· 2007
[cited by applicant]
US 20080044413A1
· Hammond
· 2008
[cited by applicant]
US 20080145420A1
· Simon
· 2008
[cited by applicant]
US 20090130089A9
· Smith
· 2009
[cited by applicant]
US 20100093979A1
· Lazar
· 2010
[cited by applicant]
US 20100184959A1
· Guler-Gane
· 2010
[cited by applicant]
US 20100279932A1
· Ledbetter
· 2010
[cited by applicant]
US 20100279939A1
· Fries
· 2010
[cited by applicant]
US 20110110852A1
· Miller
· 2011
[cited by applicant]
US 20110129412A1
· Gazit-Bornstein
· 2011
[cited by applicant]
US 20120039870A9
· Dolk
· 2012
[cited by applicant]
US 20120045432A9
· Yu
· 2012
[cited by applicant]
US 20120142593A1
· Zhao
· 2012
[cited by examiner]
US 20120269830A1
· Horowitz
· 2012
[cited by applicant]
US 20130095097A1
· Blankenship
· 2013
[cited by applicant]
US 20130280167A1
· Rodriguez
· 2013
[cited by applicant]
US 20140010809A1
· Ledbetter
· 2014
[cited by applicant]
US 20140154252A1
· Thompson
· 2014
[cited by applicant]
US 20150004167A1
· Wu
· 2015
[cited by applicant]
US 20150038682A1
· Tsurushita
· 2015
[cited by applicant]
US 20150259420A1
· Triebel
· 2015
[cited by applicant]
US 20190330360A1
· Wang
· 2019
[cited by applicant]
US 20190330374A1
· Wang
· 2019
[cited by applicant]
US 20190338040A1
· Keyt
· 2019
[cited by applicant]
US 20190338041A1
· Baliga
· 2019
[cited by applicant]
US 20200392239A1
· Wang
· 2020
[cited by applicant]
US 20210032357A1
· Keyt
· 2021
[cited by applicant]
US 20210087273A1
· Baliga
· 2021
[cited by applicant]
US 20210163600A1
· Keyt
· 2021
[cited by applicant]
US 20210380701A1
· Baliga
· 2021
[cited by applicant]
US 20210388098A1
· Keyt
· 2021
[cited by applicant]
US 20220106398A1
· Baliga
· 2022
[cited by applicant]
US 20220106399A1
· Baliga
· 2022
[cited by applicant]
US 20220169751A1
· Wang
· 2022
[cited by applicant]
US 20220177595A1
· Wang
· 2022
[cited by applicant]
US 20220267415A1
· Ku
· 2022
[cited by applicant]
US 20220289856A1
· Amoury
· 2022
[cited by applicant]
US 20220306760A1
· Keyt
· 2022
[cited by applicant]
US 20220340676A1
· Baliga
· 2022
[cited by applicant]
US 20220372142A1
· Baliga
· 2022
[cited by applicant]
US 20220403009A1
· Hinton
· 2022
[cited by applicant]
US 20230058162A1
· Hinton
· 2023
[cited by applicant]
US 20230073926A1
· Keyt
· 2023
[cited by applicant]
US 20230174660A1
· Wang
· 2023
[cited by applicant]
US 20230203119A1
· Baliga
· 2023
[cited by applicant]
US 20230203173A1
· Wang
· 2023
[cited by applicant]
US 20230212293A1
· Keyt
· 2023
[cited by applicant]
US 20230279111A1
· Keyt
· 2023
[cited by applicant]
US 20240002514A1
· Keyt
· 2024
[cited by applicant]
US 20240002526A1
· Chen
· 2024
[cited by applicant]
US 20240076392A1
· Hinton
· 2024
[cited by applicant]
US 20250051473A1
· Li
· 2025
[cited by applicant]
AU 697387
· 1996
[cited by applicant]
AU 708301
· 1996
[cited by applicant]
AU 2004297218
· 2005
[cited by applicant]
CA 2358520
· 2000
[cited by applicant]
CA 2662701
· 2008
[cited by applicant]
EP 642585
· 1995
[cited by applicant]
EP 1169352
· 2002
[cited by applicant]
EP 1301541
· 2003
[cited by applicant]
EP 1617870
· 2006
[cited by applicant]
EP 1833848
· 2007
[cited by applicant]
EP 2219458
· 2010
[cited by applicant]
EP 2254592
· 2010
[cited by applicant]
EP 2264163
· 2010
[cited by applicant]
EP 2300498
· 2011
[cited by applicant]
EP 2465871
· 2012
[cited by applicant]
EP 2649184
· 2013
[cited by applicant]
EP 2655415
· 2013
[cited by applicant]
EP 2771361
· 2014
[cited by applicant]
EP 2962103
· 2016
[cited by applicant]
JP 2004525630
· 2004
[cited by applicant]
JP 2005522998
· 2005
[cited by applicant]
WO 1989001975
· 1989
[cited by applicant]
WO 1998030591
· 1998
[cited by applicant]
WO 1998030592
· 1998
[cited by applicant]
WO 2001012820
· 2001
[cited by applicant]
WO 2001014424
· 2001
[cited by applicant]
WO 2004110143
· 2004
[cited by applicant]
WO 2005103081
· 2005
[cited by applicant]
WO 2006052641
· 2006
[cited by applicant]
WO 2006130458
· 2006
[cited by applicant]
WO 2008140477
· 2008
[cited by applicant]
WO 2009013620
· 2009
[cited by applicant]
WO 2009130575
· 2009
[cited by applicant]
WO 2010105256
· 2010
[cited by applicant]
WO 2013061098
· 2013
[cited by applicant]
WO 2013087913
· 2013
[cited by applicant]
WO 2013120012
· 2013
[cited by applicant]
WO 2013150138
· 2013
[cited by applicant]
WO 2013158748
· 2013
[cited by applicant]
WO 2013188870
· 2013
[cited by applicant]
WO 2014022592
· 2014
[cited by applicant]
WO 2014124457
· 2014
[cited by applicant]
WO 2014165093
· 2014
[cited by applicant]
WO WO2014165093A2
· 2014
[cited by examiner]
WO 2014207064
· 2014
[cited by applicant]
WO 2015037000
· 2015
[cited by applicant]
WO 2015053887
· 2015
[cited by applicant]
WO 2015103072
· 2015
[cited by applicant]
WO 2015120474
· 2015
[cited by applicant]
WO 2015151081
· 2015
[cited by applicant]
WO 2015153912
· 2015
[cited by applicant]
WO 2016118641
· 2016
[cited by applicant]
WO 2016141303
· 2016
[cited by applicant]
WO 2016154593
· 2016
[cited by applicant]
WO 2016168758
· 2016
[cited by applicant]
WO 2017059380
· 2017
[cited by applicant]
WO 2017059387
· 2017
[cited by applicant]
WO 2017196867
· 2017
[cited by applicant]
WO 2018017761
· 2018
[cited by applicant]
WO 2018017763
· 2018
[cited by applicant]
WO 2018017888
· 2018
[cited by applicant]
WO 2018017889
· 2018
[cited by applicant]
WO 2018187702
· 2018
[cited by applicant]
WO 2019165340
· 2019
[cited by applicant]
WO 2019169314
· 2019
[cited by applicant]
WO 2020086745
· 2020
[cited by applicant]
WO 2020163646
· 2020
[cited by applicant]
WO 2021030688
· 2021
[cited by applicant]
WO 2021034646
· 2021
[cited by applicant]
WO 2021041250
· 2021
[cited by applicant]
WO 2021055765
· 2021
[cited by applicant]
WO 2021141902
· 2021
[cited by applicant]
WO 2021216756
· 2021
[cited by applicant]
WO 2021231639
· 2021
[cited by applicant]
WO 2022026475
· 2022
[cited by applicant]
WO 2022109023
· 2022
[cited by applicant]
WO 2022177870
· 2022
[cited by applicant]
WO 2022178047
· 2022
[cited by applicant]
WO 2023064766
· 2023
[cited by applicant]
WO 2023064900
· 2023
[cited by applicant]
WO 2023150677
· 2023
[cited by applicant]
WO 2023178253
· 2023
[cited by applicant]
WO 2024073700
· 2024
[cited by applicant]
WO 2024138072
· 2024
[cited by applicant]
WO 2024148336
· 2024
[cited by applicant]
WO 2024148339
· 2024
[cited by applicant]
WO 2024229151
· 2024
[cited by applicant]
U.S. Appl. No. 18/252,759, Specification, Claims, Abstract and Drawings filed May 12, 2023 with U.S. Patent Office.
[cited by applicant]
U.S. Appl. No. 18/261,145, Specification, Claims, Abstract and Drawings filed Jul. 12, 2023 with U.S. Patent Office.
[cited by applicant]
U.S. Appl. No. 18/463,194, Specification, Claims, Abstract and Drawings filed Sep. 7, 2023 with U.S. Patent Office.
[cited by applicant]
Aggarwal, B., et al. (2012), “Historical Perspectives on Tumor Necrosis Factor and Its Superfamily: 25 Years Later, a Golden Journey”, Blood, 119(3): 651-665.
[cited by applicant]
Albrecht, H., et al. (2006), “Recombinant Antibodies: From the Laboratory to the Clinic”, Cancer Biotherapy & Radiopharmaceuticals, vol. 21: 285-304.
[cited by applicant]
Ammann, J., et al. (2014), “Development and use of IgM/J-Chain Fusion Proteins for Chacterization of Immunoglobulin Superfamily Ligand-Receptor Interactions”, Current Protocols in Protein Science, Supplement 75.
[cited by applicant]
Ammann, J., et al., (2012), “Detection of weak receptor-ligand interactions using IgM and J-chain-based fusion proteins”, European Journal of Immunology, 42:1354-1356.
[cited by applicant]
Andersen, J., et al., “Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding”, 2014, Journal of Biological Chemistry, vol. 289, No. 19, pp. 13492-13502.
[cited by applicant]
Arnold, J., et al., (2005), “Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin”, The Journal of Biological Chemistry, vol. 280(32): 29080-29087.
[cited by applicant]
Azuma, Y., et al., “Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma”, 2007, Clin Cancer Res, vol. 13 (No. 9), pp. 2745-2750 with correction on article.
[cited by applicant]
Bacac, M., et al., (2018), “CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies”, Clinical Cancer Research, 24(19): 4785-4797, includes supplementary methods, Binding to CD20…
[cited by applicant]
Bakema et al, “Immunoglobulin A, A next generation of therapeutic antibodies?”, mAbs, Aug. 2011, vol. 3, No. 4, 352-361.
[cited by applicant]
Baliga, R., et al, (2019), “IGM-2323: High Avidity IgM-based CD20×CD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release”, Abstract 1574 at American Society of Hematology Annual Meet…
[cited by applicant]
Baliga, R., et al., (2016) “High Avidity Anti-CD20 IgM Antibody for enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells”, Poster Presented at the PEGS Boston Meeting Apr. 25-29, 2016.
[cited by applicant]
Beers, S., et al., (2010), “Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection”, Blood, 115(25): 5191-5201.
[cited by applicant]
Binz, et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nature Biotechnology 2005, vol. 23, No. 10, pp. 1257-1268.
[cited by applicant]
Bornstein, G., et al., (2010), “Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies”, Invest New Drugs, 28:561-574.
[cited by applicant]
Bortoletto, N., et al., (2002), “Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells”, Eur. J. Immunol, 32: 3102-3107.
[cited by applicant]
Bowles, J., et al., (2006), “Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab”, Blood, 108(8): 2648-2654.
[cited by applicant]
Braathen, R., et al. (2002), “The Carboxyl-terminal Domains of IgA and IgM Direct Isotype-specific Polymerization and Interaction with the Polymeric Immunoglobulin Receptor”, The Journal of Biological Chemistry, 277(45)…
[cited by applicant]
Brodska et al., “Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility”, Cancer Immunology Research, Aug. 2016, pp. 815-819, vol. 4, No. 10.
[cited by applicant]
Brüggemann, M., et al., (1987), “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies”, J. Exp. Med, 166: 1351-1361.
[cited by applicant]
Cao, Y., et al., (2011), “Targeting cell surface B2-microglobulin by pentameric IgM antibodies”, Br J Haematol, 154: 111-121.
[cited by applicant]
Casset, F., et al., (2003), “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design”, Biochemical and biophysical Research Communications, 307: 198-205.
[cited by applicant]
Castro, C., et al., (2014), “Putting J chain back on the map: how might its expression define plasma cell development?”, The Journal of Immunology, 193: 3248-3255.
[cited by applicant]
Cazet et al., “Tumour-associated carbohydrate antigens in breast cancer,” Breast Cancer Research 2010, vol. 12, No. 3, p. 204.
[cited by applicant]
Chen, Y., et al., (1999), Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen, 293: 865-881.
[cited by applicant]
Chintalacharuvu, K.R., et al., “Hybrid IgA2/igG1 Antibodies with Tailor-Made Effector Functions”, Clinical Immunology, Oct. 2001, pp. 21-31, vol. 101, No. 1, pp. 21-31.
[cited by applicant]
Chu, S., et al., (2014), “Immunotherapy with Long-Lived Anti-CD20×Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-mediated Killing of Human B Cell lines and Circulating and Lymphoid B Cells in Monkeys: A Potenti…
[cited by applicant]
Ciric B., et al. (2009), “Effect of Valency on Binding Properties of the Antihuman IgM Monoclonal Antibody 202”, Hybridoma, vol. 14. No. 6, pp. 537-544.
[cited by applicant]
Clackson et al., “ Making antibody fragments using phage display libraries” Nature 1991, vol. 352, pp. 624-628.
[cited by applicant]
Colman, P.M. (1994) “Effects of amino acid sequence changes on antibody-antigen interactions”, Biomolecular Research Institute, 55th Forum in Immunology, pp. 33-35.
[cited by applicant]
Cregger, M., et al., (2006), “Immunohistochemistry and Quantitative Analysis of Protein Expression”, Arch Pathol Lab Med., 130: 1026-1030.
[cited by applicant]
Czajkowsky D., et al., (2009), “The human IgM pentamer is a mushroom-shaped molecule with a flexural bias,” PNAS, 106(35): 14960-14965.
[cited by applicant]
Czuczman, M., et al., (2008), “Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional …
[cited by applicant]
Davis et al., “On the structure of polymeric IgM,” Eur. J. Immunol. 1988, vol. 18, No. 7, pp. 1001-1008.
[cited by applicant]
Davis, A., et al., (1989), “IgM—Molecular requirements for its assembly and function”, Immunology Today, 10(4): 118-128.
[cited by applicant]
Davis, T., et al., (1999), “Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab”, J. Clin Oncol. 17: 1851-1857.
[cited by applicant]
Davis, T., et al., (2000), “Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment”, Journal of Clinical Oncology, 18(17): 3135-3143.
[cited by applicant]
De Pascalis, R., et al., (2002), “Grafting of “Abbreviated” Complementarity-Determining Regions Containing specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclona…
[cited by applicant]
Dennis, M., et al. (2002), “Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins”, J. Biol. Chem. 277(38): 35035-35043.
[cited by applicant]
Dennis, M., et al., (2012), “Transferrin Antibodies into the Brain”, Neuropsychopharmacology Reviews, 37: 302-303.
[cited by applicant]
Dorai et al., “The complete nucleotide sequence of a human immunoglobulin genomic Cu gene,” GenBank Accession Number X14940.1, Nucleic Acids Research 1989, vol. 17, No. 15, p. 6412.
[cited by applicant]
Ducry, L., et al., “Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies”, 2010, Bioconjug. Chem. 21, 5-13.
[cited by applicant]
Duramad, O., et al., (2014), “IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma”, IGM Biosciences, Inc.—Research and Development, SRI International—Can…
[cited by applicant]
Edwards, B., et al., (2003), “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, J. Mol. Biol, 334: 103-118.
[cited by applicant]
Ellman, “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins,” Meth. Enzym. 1991, vol. 202, pp. 301-336.
[cited by applicant]
Fournier et al., “Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future,” BioDrugs. 2013, vol. 27, No. 1, pp. 35-53.
[cited by applicant]
Frutiger, S., et al., 1992, “Disulfide Bond Assignment in Human J Chain and its Covalent Pairing with Immunoglobulin M”, Biochemistry, vol. 31, pp. 12643-12647.
[cited by applicant]
Fukushima, N., et al., (2002), “Chacterization of Recombinant Monoclonal IgA Anti-PDC-E2 Autoantibodies Derived From patients with PBC”, Hepatology: 35: 1383-1392.
[cited by applicant]
Gaetano, N., et al., (2003), “Complement Activation Determines the Therapeutic Activity of Rituximab in Vivo”, The Journal of Immunology, 171: 1581-1587.
[cited by applicant]
Garcia-Pardo et al., “ J chain is covalently bound to both monomer subunits in human secretory IgA,” J. Biol. Chem. 1981, vol. 256, pp. 11734-11738.
[cited by applicant]
Ghielmini, M., (2004), “Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule”, Blood, 1…
[cited by applicant]
Gibson Josefine, “Anti-PD-L1 for metastatic triple-negative breast cancer.”, The Lancet. Oncology Jun. 2015, (Jun. 2015), vol. 16, No. 6, ISSN 1474-5488, p. e264, XP002765988.
[cited by applicant]
Gilmour, J.E.M., et al. (2008), “Effect of the presence or absence of J Chain on expresion of recombinant anti-kell immunoglobulin”, Transfusion Medicine, 18: 167-174.
[cited by applicant]
Golay, J., et al. (2012), “Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays”, Archives of Biochemistry and Biophysics, 526: 146-153.
[cited by applicant]
Goswami et al., “Developments and challenges for mAb-Based therapeutics,” Antibodies 2013, vol. 2, No. 3, pp. 452-500.
[cited by applicant]
Hagenbeek, A., et al., (2009), “Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma”, Blood, 114(22): 935, 6 pages.
[cited by applicant]
Haidar, JH., et al., (2003), “Loss of CD20 expression in relapsed lymphomas after rituximab therapy”, Eur J. Haematol, 70: 330-332.
[cited by applicant]
Harao M., et al. , (2014), “Abstract LB-263: Enhancing of CD8+ tumor-infiltrating lymphocyte expansion from triple-negative breast cancer patients using of 41BB costimulation”, American Associaton for Cancer Research, U…
[cited by applicant]
Hay, M., et al., (2014), “Clinical development success rates for investigational drugs”, Nature Biology, 32(1): 40-51.
[cited by applicant]
Hensel, F., et al., (2013), “Early development of PAT-SM6 for the treatment of melanoma”, Melanoma Research, 23(4): 264-275.
[cited by applicant]
Hirayasu, K. and Arase, H., “Immunoglobulin mu heavy chain, partial [
[cited by applicant]
Hopp, J., et al., (2010), “The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein”, vol. 23(11): 827-834.
[cited by applicant]
Houghton, J., et al., (2015), “Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer”, PNAS, vol. 112, No. 52: 15850-15855.
[cited by applicant]
Hsu, D., et al., (1999), “A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees”, Transplantation, 68(4): 545-554.
[cited by applicant]
Jeon, H., et al., (2014), “Structure and Cancer Immunotherapy of the B7 Family Member B7x”, Cell Rep., vol. 9(3): 1089-1098.
[cited by applicant]
Johansen, F., et al., (2000), “Role of J Chain in Secretory Immunoglobulin Formation”, Scand. J. Immunol., 52: 240-248.
[cited by applicant]
Johansen, F., et al., (2001), “The J Chain Is Essential for Polymeric Ig Receptor-Mediated Epithelial Transport of IgA”, The Journal of Immunology, 167: 5185-5192.
[cited by applicant]
Johnson, R., et al. (2012) “Biological Activity of Anti-CD20 Multivalent HPMA Copolymer-Fab′ Conjugates”, Biomacromolecules, vol. 13, pp. 727-735.
[cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature 1986, vol. 321, pp. 522-525.
[cited by applicant]
Jones, A., et al., (2007), “Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation”, Pharm Res., 24(9): 1759-1771.
[cited by applicant]
Joos, B., et al., 2006, “Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)”, Antimicrob Age…
[cited by applicant]
Jubala, C.M., et al. (2005), “CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma” Vet Pathol 42: 468-476.
[cited by applicant]
Klein, J., et al., (2014,) “Design and characterization of structured protein linkers with differing flexibilities” Protein Eng Des Sel 27, 325-330.
[cited by applicant]
Klimovich, V. B., (2011), “IgM and Its Receptors: Structural and Functional Aspects”, Biochemistry, 76(5): 534-549.
[cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature 1975, vol. 256, No. 495-7.
[cited by applicant]
Kragten, E., et al., (1995), “Site-specific analysis of the N-Glycans on Murine Polymeric Immunoglobulin A. Using Liquid Chromatography/Electrospray Mass Spectrometry”, vol. 30, 1679-1686.
[cited by applicant]
Krugmann, S., et al. (1997), “Structural Requirements for Assembly of Dimeric IgA Probed by Site-Directed Mutagenesis of J Chain and a Cysteine Residue of the α-chain CH2 Domain”, The Journal of Immunology, 159: 244-249.
[cited by applicant]
Ksiezak-Reding, H., et al., 1988, “Alz 50, a monoclonal antibody to Alzheimer's disease antigen, cross-reacts with tau proteins from bovine and normal human brain”, J. Biol. Chem. 263, 7943-7947.
[cited by applicant]
Lamminmäki, U., et al., (2001), “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β Estradiol”, The Journal of Biological Chemistry, vol. 276(39): 36687-36694.
[cited by applicant]
Lederman, S., et al. (1991), “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4”, Molecular Immunology, 28(11): 1171-1181.
[cited by applicant]
Lewis, A.K., et al., 2014, “Open and Closed Conformations of the Isolated Transmembrane Domain of Death Receptor 5 Support a New Model of Activation” Biophys J 106, L21-L24.
[cited by applicant]
Liedtke, M., et al., (2012), “Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia” Haematologica 97(1), 30-37.
[cited by applicant]
Lines, J., et al., (2014), “VISTA Is an Immune Checkpoint Molecule for Human T Cells”, Cancer Research 74(7): 1924-1932.
[cited by applicant]
Liu, X., et al., (2005), “Preliminary study on recombination of J-HNP-1 and its antibacterial effect in vitro” Shijie Huaren Xiaohua Zazhi, 13(22), 2640-2644, English Abstract Only Available.
[cited by applicant]
Liu, X., et al., (2005), “Recombinant of J chain-HNP-1 cDNA and the construction of expression vector”, Di-San Junyi Daxue Xuebao, 27(8), 697-699. English Abstract Only Available.
[cited by applicant]
Liu, Xianhua, et al., 2006, “Expression Detection of the gene of α-defensin-1 with J chain in the transfected COS-7 cells”, Chin Crit Care Med, vol. 18, No. 2, pp. 71 to 73 with Full English translation.
[cited by applicant]
Lloyd, C., et al., (2009), “Modelling the human immune response: performance of a 10″ human antibody repertoire against a broad panel of therapeutically relevant antigens”, Protein Engineering, Design & Selection, 22(3)…
[cited by applicant]
MacCallum R., et al. (1996), “Antibody-antigen Interactions: Contact Analysis and binding Site Topography”, J. Mol. Bio. 262: 732-745.
[cited by applicant]
Maekawa, N., et al., (2014), “Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade”, PLOS One, vol. 9(6), e98415.
[cited by applicant]
Maloney, D., et al., (1997), “IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma”, Blood, 90(6): 2188-2195.
[cited by applicant]
Mandikian, D., et al., (2018), “Relative Target Affinities of T Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model”, Mol Cancer Ther., 17(4): 776-785, doi: 10.1158/1535-7163.MCT-…
[cited by applicant]
Marcus, R., et al., (2017), “Obinutuzumab for the First-Line Treatment of Follicular Lymphoma”, N Engl. J. Med. 377(14): 1331-44.
[cited by applicant]
Mariuzza, R. A., (1987), “The Structural Basis of Antigen-Antibody Recognition”, vol. 16: 139-159.
[cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J. Mol. Biol. 1991, vol. 222, pp. 582-597.
[cited by applicant]
Mestecky, J., et al., (1973), “J-chain of polymeric IgA myeloma proteins”, Protides of the Biological Fluids, vol. 20: 279-283 , Abstract Only Available.
[cited by applicant]
Meyer et al., “Improved In Vivo Anti-Tumor Effects of IgA-Her2 Antibodies Through Half-Life Extension and Serum Exposure Enhancement by FcRn Targeting”, mAbs, Jan. 2016, pp. 87-98, vol. 8, Issue 1.
[cited by applicant]
Mølhøj, M., et al., (2007), “CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis”, Molecular Immunology 44: 1935-1943.
[cited by applicant]
Mongini, P., et al., (1995), “Human B Cell Activation, Effect of T Cell Cytokines on the Physicochemical Binding Requirements for Achieving Cell cycle Progression via the Membrane IgM Signaling Pathway”, The Journal of …
[cited by applicant]
Mordenti, J., et al. (1999), “Intraocular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation”, Toxicological Scien…
[cited by applicant]
Mordenti, J., et al., (1999), “Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration”, In…
[cited by applicant]
Morrison et al., “ Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” PNAS 1984, vol. 81, pp. 6851-6855.
[cited by applicant]
Mosmann, T.R., et al. (1978), “Modification and Fate of J. Chain in myeloma cells in the presence and absence of polymeric immunoglobulin secretion”, Eur. J. Immunol. 8: 84-101.
[cited by applicant]
Müller, M. et al., (2012), “Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain” MAbs 4, 673-685.
[cited by applicant]
NCBI Reference Sequence (2018): NP_653247.1, 17.04.2013, Immunoglobulin J chain precursor [
[cited by applicant]
Niles, M., et al., (1995), “Polymer IgM assembly and secretion in lymphoid and nonlymphoid cell lines: evidence that J chain is required for pentamer IgM synthesis”, Proc. Natl. Acad. Sci. USA, 92: 2884-2888.
[cited by applicant]
Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199.
[cited by applicant]
Nocentini, G., et al., (1997), “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis”, Proc. Natl. Acad. Sci. U.S.A. 94, 6216-6221.
[cited by applicant]
Non-final Office Action issued in U.S. Appl. No. 15/764,859 on Aug. 6, 2019.
[cited by applicant]
Noren et al., “A general method for site-specific incorporation of unnatural amino acids into proteins,” Science 1989, vol. 244, p. 182-188.
[cited by applicant]
Ofei et al., “Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control inpatients with NIDDM,” Diabetes 1996, vol. 45, pp. 881-885.
[cited by applicant]
Office Action issued Sep. 27, 2019 in U.S. Appl. No. 15/764,870.
[cited by applicant]
Padlan, E., et al.., (1989), “Structure of an antibody-antigen complex: crystal structure of the HyHel-10 Fab-lysozyme complex;”, Proc. Natl. Acad. Sci. USA, vol. 86: 5938-5942.
[cited by applicant]
Palanichamy Arumugam et al, “Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.”, Journal of Immunology (Baltimore, MD. : 1950) Jul. 15, 2014, (Jul. 15, 2014), vol. 193, No.…
[cited by applicant]
Pardoll, D.M., (2012), “The blockade of immune checkpoints in cancer immunotherapy” Nat. Rev. Cancer 12(4): 252-264.
[cited by applicant]
Pascal, V., et al. (2012) “Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 Target cells”, Haematologica, the Hematology Jour…
[cited by applicant]
Paterson, J., et al., (2006), “The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas”, Haematologica 91: 772-780.
[cited by applicant]
Paulik et al., “Drug-antibody conjugates with anti-HIV activity,” Biochem. Pharmacol. 1999, vol. 58, pp. 1781-1790.
[cited by applicant]
Ponders and Richards, “Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes,” J. Mol. Biol. 1987, vol. 193, pp. 775-791.
[cited by applicant]
Postow, M., et al., (2015), “Immune Checkpoint Blockade in Cancer Therapy”, J. Clin. Oncol. 33(17): 1974-1982.
[cited by applicant]
Presta, “Antibody engineering,” Curr. Op. Struct. Biol. 1992, vol. 2, pp. 593-596.
[cited by applicant]
Rabbitts et al. “Human immunoglobulin heavy chain genes: evolutionary comparisons of C mu, C delta and C gamma genes and associated switch sequences,” GenBank Accession Number CAB37838, Nucleic Acids Research 1981 vol. …
[cited by applicant]
Raju et al., “Potential therapeutic roles for antibody mixtures,” Exp. Op. Biol. Ther. 2013, vol. 13, No. 10, pp. 1347-1352.
[cited by applicant]
Randall, T., et al., (1992), “Direct Evidence That J Chain Regulates the Polymeric Structure of IgM in Antibody-secreting B Cells”, The Journal of Biological Chemistry, vol. 267(25), 18002-18007.
[cited by applicant]
Rasche, L., et al., (2015), “GRP78-directed immunotherapy in relapsed or refractory multiple myeloma—results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6”, Haematologica, 100(3): 377-384.
[cited by applicant]
Redwan, E., et al. (2006), “Recombinant human J-chain: fix the protein aggregations and yield maximize” Human Antibodies 15, 95-102.
[cited by applicant]
Request for Supplement Examination as filed on Jun. 18, 2021 with USPTO re U.S. Pat. No. 9,951,134, issued Apr. 24, 2018.
[cited by applicant]
Rezvani, A., et al., (2011), “Rituximab Resistance”, Best Pract Res Clin Haematol, 24(2): 203-216.
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature 1988, vol. 332, pp. 323-329.
[cited by applicant]
Roopenian, D., et al., (2007), “FcRn: the neonatal Fc receptor comes of age”, Nature Reviews, vol. 7, 715-725.
[cited by applicant]
Rossi, E., et al. (2008) “Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics”, Cancer Res, vol. 68(20), pp. 8384-8392.
[cited by applicant]
Rudikoff, S., et al., (1982), “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA, 79: 1979-1983.
[cited by applicant]
Saber, H., et al., (2017), “An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection”, Regulatory Toxicology and Pharmacology, 90: 144-152.
[cited by applicant]
Seifert, O., et al., (2012), “The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificty”, Protein engineering, Design & Selection, vol. 25: 603-612.
[cited by applicant]
Singer, M., et al., “Genes and Genomes”, Moscow, “Mir”, 1998, vol. 1: 63-64, no translation available, reference is believed to be a standard textbook reference on antibody structure.
[cited by applicant]
Smith, E., et al., (2015), “A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys”, Scientific Reports, 5: 17943, 12 pages.
[cited by applicant]
Smith, R. et al., (1995), “Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4” The Journal of Immunology 154, 2226-2236.
[cited by applicant]
Sørensen, V., et al., (2000), “Structural requirements for incorporation of J chain into human IgM and IgA”, International Immunology, vol. 12(1): 19-27.
[cited by applicant]
Stancovski, I., et al. (1991), “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth”, Cell Biology, Proc. Natl. Acad. Sci. USA, vol. 88, 8691-8695.
[cited by applicant]
Strohl, W., et al., (2015), “Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters”, BioDrugs, 29: 215-239.
[cited by applicant]
Sun, L., et al., (2015), “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies”, Immunotherapy, vol. 7(287), 287ra70, 11 pages.
[cited by applicant]
Supplemental Examination Certificate Issued on Aug. 16, 2021 with USPTO re U.S. Pat. No. 9,951,134.
[cited by applicant]
Symersky, J., et al., (2000), “Expression of the recombinant human immunoglobulin J Chain in
[cited by applicant]
Tabrizi, M., et al. (2010), “Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease”, The AAPS Journal, vol. 12, No. 1, pp. 33-43.
[cited by applicant]
Tavolaro, S., et al. (2013), “IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells”, Leukemia Research, 37: 455-462.
[cited by applicant]
Tchoudakova, A., et al., 2009, “High level expression of functional human IgMs in human PER.C6 cells”, MAbs 1, 163-171.
[cited by applicant]
Teachey, D., et al., (2013), “Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy”, Blood Journal, DOI 10.1182/blood-2013-02-48…
[cited by applicant]
Tussiwand, R., et al., (2012), “BAFF-R expression correlates with positive selection of immature B cells”, European Journal of Immunology, 42: 206-216.
[cited by applicant]
U.S. Appl. No. 18/052,388, Specification, Claims, Abstract and Drawings filed Nov. 3, 2022 with U.S. Patent Office.
[cited by applicant]
Vajdos, F., et al., (2002), “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J. Mol. Biol. 320: 415-428.
[cited by applicant]
Valley, C., et al., (2012), “Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Induces Death Receptor 5 Networks That Are Highly Organized”, Journal of Biological Chemistry, 287 (25): 21265-21278.
[cited by applicant]
Van Imhoff, G., et al., (2017), “Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study”, Journal of Clinical Oncology, 35(5): 544-551.
[cited by applicant]
Vasquez, K., et al., (2011), “Quantitative Whole Body biodistribution of fluorescent-labeled Agents by Non-Invasive Tomographic Imaging”, PLOS one, vol. 6, Issue 6, e20594.
[cited by applicant]
Vcelar et al., “Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data,” AIDS 2007, vol. 21, No. 16, pp. 2161-2170.
[cited by applicant]